Kadmon (NYSE:KDMN)‘s stock had its “positive” rating reissued by stock analysts at Piper Jaffray Companies in a research note issued on Tuesday, The Fly reports. They presently have a $9.00 price target on the stock, up from their previous price target of $7.00. Piper Jaffray Companies’ price objective suggests a potential upside of 95.23% from the company’s previous close.
KDMN has been the subject of a number of other reports. Zacks Investment Research lowered shares of Kadmon from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Jefferies Group lifted their price objective on shares of Kadmon to $16.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a research note on Friday, December 15th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $10.21.
Kadmon (NYSE KDMN) traded down $0.23 during trading on Tuesday, reaching $4.61. 2,654,495 shares of the company were exchanged, compared to its average volume of 1,205,268. Kadmon has a fifty-two week low of $2.05 and a fifty-two week high of $5.86. The stock has a market cap of $376.70, a price-to-earnings ratio of -2.65 and a beta of 5.39.
WARNING: “Kadmon (KDMN) Receives “Positive” Rating from Piper Jaffray Companies” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/kadmon-kdmn-receives-positive-rating-from-piper-jaffray-companies.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.